Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 2
2007 1
2008 2
2009 2
2010 3
2012 2
2015 3
2016 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, Schauer U, Qaqundah P, Poulin Y, Kristjansson S, von Berg A, Nieto A, Boguniewicz M, Paller AS, Dakovic R, Ring J, Luger T. Sigurgeirsson B, et al. Among authors: vertruyen a. Pediatrics. 2015 Apr;135(4):597-606. doi: 10.1542/peds.2014-1990. Epub 2015 Mar 23. Pediatrics. 2015. PMID: 25802354 Free article. Clinical Trial.
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. Vesikari T, et al. Among authors: vertruyen af. Pediatr Infect Dis J. 2017 Feb;36(2):209-215. doi: 10.1097/INF.0000000000001406. Pediatr Infect Dis J. 2017. PMID: 27846055 Clinical Trial.
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasons.
Claeys C, Zaman K, Dbaibo G, Li P, Izu A, Kosalaraksa P, Rivera L, Acosta B, Arroba Basanta ML, Aziz A, Cabanero MA, Chandrashekaran V, Corsaro B, Cousin L, Diaz A, Diez-Domingo J, Dinleyici EC, Faust SN, Friel D, Garcia-Sicilia J, Gomez-Go GD, Antoinette Gonzales ML, Hughes SM, Jackowska T, Kant S, Lucero M, Malvaux L, Mares Bermudez J, Martinon-Torres F, Miranda M, Montellano M, Peix Sambola MA, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Salamanca de la Cueva I, Sokal E, Soni J, Szymanski H, Ulied A, Schuind A, Jain VK, Innis BL; Flu4VEC Study Group. Claeys C, et al. Lancet Child Adolesc Health. 2018 May;2(5):338-349. doi: 10.1016/S2352-4642(18)30062-2. Epub 2018 Mar 5. Lancet Child Adolesc Health. 2018. PMID: 30169267 Clinical Trial.
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD. Lum LC, et al. Among authors: vertruyen a. Vaccine. 2010 Feb 10;28(6):1566-74. doi: 10.1016/j.vaccine.2009.11.054. Epub 2009 Dec 8. Vaccine. 2010. PMID: 20003918 Clinical Trial.
A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. Hatz C, et al. Among authors: vertruyen a. Vaccine. 2012 Jul 6;30(32):4820-7. doi: 10.1016/j.vaccine.2012.05.013. Epub 2012 May 22. Vaccine. 2012. PMID: 22626675 Clinical Trial.
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza Vaccine.
Danier J, Rivera L, Claeys C, Dbaibo G, Jain VK, Kosalaraksa P, Woo W, Yanni E, Zaman K, Acosta B, Amanullah A, Ariza M, Luisa Arroba Basanta M, Bavdekar A, Carmona A, Cousin L, Diaz A, Diez-Domingo J, Cagri Dinleyici E, Faust SN, Garcia-Sicilia J, Gomez-Go GD, Antionette Gonzales L, Hacimustafaoglu M, Hughes SM, Izu A, Jackowska T, Kant S, Lucero M, Mares Bermudez J, Martinón-Torres F, Montellano M, Prymula R, Puthanakit T, Ruzkova R, Sadowska-Krawczenko I, Soni J, Szymanski H, Ulied A, Schuind A, Innis BL; Flu4VEC Study Group. Danier J, et al. Pediatr Infect Dis J. 2019 Aug;38(8):866-872. doi: 10.1097/INF.0000000000002387. Pediatr Infect Dis J. 2019. PMID: 31306399 Clinical Trial.
Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group. Gossger N, et al. JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85. JAMA. 2012. PMID: 22318278 Clinical Trial.
19 results